|
1
|
Nur U, Quaresma M, De Stavola B, Peake M
and Rachet B: Inequalities in non-small cell lung cancer treatment
and mortality. J Epidemiol Community Health. 69:985–992. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thomas A, Chen Y, Yu T, Jakopovic M and
Giaccone G: Trends and characteristics of young non-small cell lung
cancer patients in the United States. Front Oncol. 5:1132015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aerts JG, Lievense LA, Hoogsteden HC and
Hegmans JP: Immunotherapy prospects in the treatment of lung cancer
and mesothelioma. Transl Lung Cancer Res. 3:34–45. 2014.PubMed/NCBI
|
|
4
|
Ohki S, Shibata M, Gonda K, Machida T,
Shimura T, Nakamura I, Ohtake T, Koyama Y, Suzuki S, Ohto H and
Takenoshita S: Circulating myeloid-derived suppressor cells are
increased and correlate to immune suppression, inflammation and
hypoproteinemia in patients with cancer. Oncol Rep. 28:453–458.
2012.PubMed/NCBI
|
|
5
|
Huang A, Zhang B, Wang B, Zhang F, Fan KX
and Guo YJ: Increased CD14(+)HLA-DR (−/low) myeloid-derived
suppressor cells correlate with extrathoracic metastasis and poor
response to chemotherapy in non-small cell lung cancer patients.
Cancer Immunol Immunother. 62:1439–1451. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ostrand-Rosenberg S: Myeloid-derived
suppressor cells: More mechanisms for inhibiting antitumor
immunity. Cancer Immunol Immunother. 59:1593–1600. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Parker KH, Beury DW and Ostrand-Rosenberg
S: Myeloid-Derived suppressor cells: Critical cells driving immune
suppression in the tumor microenvironment. Adv Cancer Res.
128:95–139. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Marigo I, Dolcetti L, Serafini P,
Zanovello P and Bronte V: Tumor-induced tolerance and immune
suppression by myeloid derived suppressor cells. Immunol Rev.
222:162–179. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Damuzzo V, Pinton L, Desantis G, Solito S,
Marigo I, Bronte V and Mandruzzato S: Complexity and challenges in
defining myeloid-derived suppressor cells. Cytometry B Clin Cytom.
88:77–91. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ortiz ML, Lu L, Ramachandran I and
Gabrilovich DI: Myeloid-derived suppressor cells in the development
of lung cancer. Cancer Immunol Res. 2:50–58. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dolcetti L, Peranzoni E, Ugel S, Marigo I,
Gomez A Fernandez, Mesa C, Geilich M, Winkels G, Traggiai E, Casati
A, et al: Hierarchy of immunosuppressive strength among
myeloid-derived suppressor cell subsets is determined by GM-CSF.
Eur J Immunol. 40:22–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fujimura T, Mahnke K and Enk AH: Myeloid
derived suppressor cells and their role in tolerance induction in
cancer. J Dermatol Sci. 59:1–6. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qu P, Wang LZ and Lin PC: Expansion and
functions of myeloid-derived suppressor cells in the tumor
microenvironment. Cancer Lett. 380:253–256. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schilling B, Sucker A, Griewank K, Zhao F,
Weide B, Görgens A, Giebel B, Schadendorf D and Paschen A:
Vemurafenib reverses immunosuppression by myeloid derived
suppressor cells. Int J Cancer. 133:1653–1663. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vetsika EK, Koinis F, Gioulbasani M,
Aggouraki D, Koutoulaki A, Skalidaki E, Mavroudis D, Georgoulias V
and Kotsakis A: A circulating subpopulation of monocytic
myeloid-derived suppressor cells as an independent
prognostic/predictive factor in untreated non-small lung cancer
patients. J Immunol Res. 2014:6592942014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schmid MC and Varner JA: Myeloid cells in
the tumor microenvironment: Modulation of tumor angiogenesis and
tumor inflammation. J Oncol. 2010:2010262010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Solito S, Marigo I, Pinton L, Damuzzo V,
Mandruzzato S and Bronte V: Myeloid-derived suppressor cell
heterogeneity in human cancers. Ann N Y Acad Sci. 1319:47–65. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mandruzzato S, Solito S, Falisi E,
Francescato S, Chiarion-Sileni V, Mocellin S, Zanon A, Rossi CR,
Nitti D, Bronte V and Zanovello P: IL4Ralpha+ myeloid-derived
suppressor cell expansion in cancer patients. J Immunol.
182:6562–6568. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mirsadraee S, Oswal D, Alizadeh Y, Caulo A
and van Beek E Jr: The 7th lung cancer TNM classification and
staging system: Review of the changes and implications. World J
Radiol. 4:128–134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ridge CA, McErlean AM and Ginsberg MS:
Epidemiology of lung cancer. Semin Intervent Radiol. 30:93–98.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vinay DS, Ryan EP, Pawelec G, Talib WH,
Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HM, et
al: Immune evasion in cancer: Mechanistic basis and therapeutic
strategies. Semin Cancer Biol. 35:(Suppl). S185–S198. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Parcesepe P, Giordano G, Laudanna C,
Febbraro A and Pancione M: Cancer-associated immune resistance and
evasion of immune surveillance in colorectal cancer. Gastroenterol
Res Pract. 2016:62617212016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Curiel TJ: Regulatory T cells and
treatment of cancer. Curr Opin Immunol. 20:241–246. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stewart TJ and Abrams SI: How tumours
escape mass destruction. Oncogene. 27:5894–5903. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Berzofsky JA and Terabe M: NKT cells in
tumor immunity: Opposing subsets define a new immunoregulatory
axis. J Immunol. 180:3627–3635. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Marvel D and Gabrilovich DI:
Myeloid-derived suppressor cells in the tumor microenvironment:
Expect the unexpected. J Clin Invest. 125:3356–3364. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Adams JL, Smothers J, Srinivasan R and
Hoos A: Big opportunities for small molecules in immuno-oncology.
Nat Rev Drug Discov. 14:603–622. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mahoney KM, Rennert PD and Freeman GJ:
Combination cancer immunotherapy and new immunomodulatory targets.
Nat Rev Drug Discov. 14:561–584. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sinha P and Ostrand-Rosenberg S:
Myeloid-derived suppressor cell function is reduced by Withaferin
A, a potent and abundant component of Withania somnifera root
extract. Cancer Immunol Immunother. 62:1663–1673. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vincent J, Mignot G, Chalmin F, Ladoire S,
Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C and
Ghiringhelli F: 5-Fluorouracil selectively kills tumor-associated
myeloid-derived suppressor cells resulting in enhanced T
cell-dependent antitumor immunity. Cancer Res. 70:3052–3061. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang WC, Ma G, Chen SH and Pan PY:
Polarization and reprogramming of myeloid-derived suppressor cells.
J Mol Cell Biol. 5:207–209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Feng PH, Lee KY, Chang YL, Chan YF, Kuo
LW, Lin TY, Chung FT, Kuo CS, Yu CT, Lin SM, et al:
CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and
their clinical relevance in non-small cell lung cancer. Am J Respir
Crit Care Med. 186:1025–1036. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
De Keersmaecker B, Fostier K, Corthals J,
Wilgenhof S, Heirman C, Aerts JL, Thielemans K and Schots R:
Immunomodulatory drugs improve the immune environment for dendritic
cell-based immunotherapy in multiple myeloma patients after
autologous stem cell transplantation. Cancer Immunol Immunother.
63:1023–1036. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Corzo CA, Condamine T, Lu L, Cotter MJ,
Youn JI, Cheng P, Cho HI, Celis E, Quiceno DG, Padhya T, et al:
HIF-1α regulates function and differentiation of myeloid-derived
suppressor cells in the tumor microenvironment. J Exp Med.
207:2439–2453. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kumar V and Gabrilovich DI:
Hypoxia-inducible factors in regulation of immune responses in
tumour microenvironment. Immunology. 143:512–519. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Krstic J and Santibanez JF: Transforming
growth factor-beta and matrix metalloproteinases: Functional
interactions in tumor stroma-infiltrating myeloid cells. Scientific
World Journal. 2014:5217542014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Beury DW, Parker KH, Nyandjo M, Sinha P,
Carter KA and Ostrand-Rosenberg S: Cross-talk among myeloid-derived
suppressor cells, macrophages, and tumor cells impacts the
inflammatory milieu of solid tumors. J Leukoc Biol. 96:1109–1118.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
O'Garra A, Barrat FJ, Castro AG, Vicari A
and Hawrylowicz C: Strategies for use of IL-10 or its antagonists
in human disease. Immunol Rev. 223:114–131. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Eruslanov E, Neuberger M, Daurkin I,
Perrin GQ, Algood C, Dahm P, Rosser C, Vieweg J, Gilbert SM and
Kusmartsev S: Circulating and tumor-infiltrating myeloid cell
subsets in patients with bladder cancer. Int J Cancer.
130:1109–1119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xiu B, Lin Y, Grote DM, Ziesmer SC,
Gustafson MP, Maas ML, Zhang Z, Dietz AB, Porrata LF, Novak AJ, et
al: IL-10 induces the development of immunosuppressive
CD14(+)HLA-DR (low/-) monocytes in B-cell non-Hodgkin lymphoma.
Blood Cancer J. 5:e3282015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang R, Lu M, Zhang J, Chen S, Luo X, Qin
Y and Chen H: Increased IL-10 mRNA expression in tumor-associated
macrophage correlated with late stage of lung cancer. J Exp Clin
Cancer Res. 30:622011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lievense LA, Bezemer K, Aerts JG and
Hegmans JP: Tumor-associated macrophages in thoracic malignancies.
Lung Cancer. 80:256–262. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zeni E, Mazzetti L, Miotto D, Lo Cascio N,
Maestrelli P, Querzoli P, Pedriali M, De Rosa E, Fabbri LM, Mapp CE
and Boschetto P: Macrophage expression of interleukin-10 is a
prognostic factor in nonsmall cell lung cancer. Eur Respir J.
30:627–632. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wesolowski R, Markowitz J and Carson WE
III: Myeloid derived suppressor cells-a new therapeutic target in
the treatment of cancer. J Immunother Cancer. 1:102013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Quatromoni JG and Eruslanov E:
Tumor-associated macrophages: Function, phenotype, and link to
prognosis in human lung cancer. Am J Transl Res. 4:376–389.
2012.PubMed/NCBI
|
|
46
|
Ngiow SF, Teng MW and Smyth MJ: A balance
of interleukin-12 and −23 in cancer. Trends Immunol. 34:548–555.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ostrand-Rosenberg S, Sinha P, Beury DW and
Clements VK: Cross-talk between myeloid-derived suppressor cells
(MDSC), macrophages and dendritic cells enhances tumor-induced
immune suppression. Semin Cancer Biol. 22:275–281. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Baird AM, Leonard J, Naicker KM, Kilmartin
L, O'Byrne KJ and Gray SG: IL-23 is pro-proliferative,
epigenetically regulated and modulated by chemotherapy in non-small
cell lung cancer. Lung Cancer. 79:83–90. 2013. View Article : Google Scholar : PubMed/NCBI
|
